期刊名称：CLINICAL INTERVENTIONS IN AGING
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Clinical Interventions in Aging
ISSN: 1178-1998
ISSN 1176-9092 (Print) - went to online only in 2009
An international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. Research topics include Alzheimer's disease, Dementia, Osteoporosis, Geriatrics. The journal encourages concise rapid reporting of original research and reviews in aging.
Journal Impact Factor: 1.824 (5 year impact 2.341)
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Indexed online: 
- PubMed and PubMed Central (Clin Interv Aging)
- MedLine
- American Chemical Society's 'Chemical Abstracts Service' (CAS)
- Science Citation Index Expanded (also known as SciSearch®)
- Current Contents®/Clinical Medicine
- Journal Citation Reports/Science Edition
- Embase, EMCare, Scopus and the Elsevier Bibliographic databases
- Directory of Open Access Journals (DOAJ)
- OAIster: The Open Access Initiative
Publication Processing Fees - Author Location
USA/Canada |
UK |
Rest-of-World |
|
US$2200.00 |
£1395.00 |
€1595.00 |
Aims and Scope
Clinical Interventions in Aging is an international, peer-reviewed journal focusing on the intrinsic diseases, therapies, indicators and management of functional decline during aging.
Clinical Interventions in Aging focuses on concise rapid reporting of original research and reviews in aging. Special attention will be given to papers reporting on actual or potential clinical applications leading to improved prevention or treatment of disease or a greater understanding of pathological processes. This journal is directed at a wide array of scientists, engineers, pharmacists, pharmacologists and clinical specialists working directly on biomedical applications of nanotechnology or wishing to maintain an up to date knowledge of this exciting and emerging field.
The editorial board comprises some of the most eminent scientists and experts in this field and the founding editor, Dr Rich Walker, is a distinguished researcher who has also published extensively in major international scientific and medical journals.
Key Features:
- Rapid Publication – Fast Review, Electronic Version, available before print
- International Scope
- Existing and Potential Clinical Applications
- Pharmaceutical Development
- Ideal vehicle for Symposia and Special Issues
- Original Research and Reviews
- Distinguished Editorial Board
- Rapid Publication of original studies and reviews in Anti-Aging
Subject areas
- Intrinsic diseases of aging
- Metabolic therapies
- Indicators of disease risk
- Health-oriented approach to aging (as opposed to a disease-oriented one)
- Clinical options to combat the maladaptive effects of aging
- Replacement of essential substances whose concentrations decline during aging
- Managing functional decline during senescence
- Preventing or delaying the onset of intrinsic diseases of aging
These areas are addressed through:
- Original research (full papers and concise rapid reports)
- Commissioned “state of the art” reviews
- Proposals for prospective reviews are welcomed
- Systematic reviews of individual agents, systems or devices. Such reviews will normally be commissioned
- Expert opinion and commentary
Availability
CIA is an open access online only journal, which means all articles are published as soon as they have been accepted and have author approval.
MedLine / Index Medicus
Designed to comply with the requirements of the NLM for inclusion in MedLine/Index Medicus.
Instructions to Authors
Preparation of Manuscript
Include:
- Forename(s) and surnames of authors (see Authorship section below)
- Author affiliations: department, institution, city, state, country
- Abstract 300 words
- 3–6 keywords
- Running header (shortened title)
- Corresponding author: name, physical address, phone, fax, email
- Reference list
- Double-spacing
- 3-cm margins
- Page numbers
- Clear concise language
- American spelling
- Ensure tables and figures are cited
- The preferred electronic format for text is Microsoft Word
- Manuscripts will be accepted in LaTeX as long as the native LaTeX and a PDF is also supplied
- Use International Systems of Units (SI) symbols and recognized abbreviations for units of measurement
- Do not punctuate abbreviations eg, et al, ie
- Spell out acronyms in the first instance in the abstract and paper
- Word counts are not specified. In general, shorter items range from 1000 to 3000 words and reviews from 3000 to 7,500
- Generic drug names are used in text, tables, and figures
- Suppliers of drugs, equipment, and other brand-name material are credited in parentheses (company, name, city, state, country)
- If molecular sequences are used, provide a statement that the data have been deposited in a publicly accessible database, eg, GenBank, and indicate the database accession number.
While the editors fully understand the extra challenges posed to authors whose native language is not English, we must ask that all manuscripts be reviewed and edited by a native speaker of English with expertise in that area prior to submission.
Authorship
Authorship credit should be based on:
1) Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data;
2) Drafting the article or revising it critically for important intellectual content;
3) Final approval of the version to be published; and
4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Authors should meet conditions 1, 2, 3, and 4.
When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript (3). These individuals should fully meet the criteria for authorship/contributorship defined above, and editors will ask these individuals to complete journal-specific author and conflict-of-interest disclosure forms. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as the group name. Journals generally list other members of the group in the Acknowledgments. The NLM indexes the group name and the names of individuals the group has identified as being directly responsible for the manuscript; it also lists the names of collaborators if they are listed in Acknowledgments.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.
All persons designated as authors should qualify for authorship, and all those who qualify should be listed.
Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Increasingly, authorship of multicenter trials is attributed to a group. All members of the group who are named as authors should fully meet the above criteria for authorship/contributorship.
The group should jointly make decisions about contributors/authors before submitting the manuscript for publication. The corresponding author/guarantor should be prepared to explain the presence and order of these individuals. It is not the role of editors to make authorship/contributorship decisions or to arbitrate conflicts related to authorship.
Contributors Listed in Acknowledgments
All contributors who do not meet the criteria for authorship should be listed in an acknowledgments section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chairperson who provided only general support. Authors should declare whether they had assistance with study design, data collection, data analysis, or manuscript preparation. If such assistance was available, the authors should disclose the identity of the individuals who provided this assistance and the entity that supported it in the published article. Financial and material support should also be acknowledged.
Groups of persons who have contributed materially to the paper but whose contributions do not justify authorship may be listed under such headings as “clinical investigators” or “participating investigators,” and their function or contribution should be described—for example, “served as scientific advisors,” “critically reviewed the study proposal,” “collected data,” or “provided and cared for study patients.” Because readers may infer their endorsement of the data and conclusions, these persons must give written permission to be acknowledged.
Please note: the Authorship and “Contributors Listed in Acknowledgments” sections are reprinted from the ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Dove Medical Press prepared this reprint. The ICMJE has not endorsed nor approved the contents of this reprint. The official version of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals is located at http://www.icmje.org/. Users should cite this official version when citing the document.
Related Authors
Where authors of a paper are related this should be disclosed at the time of submission. Please provide details of the family relationship between such authors.
Figures and Tables
- Submit as separate files and also as one combined file
- Submit figures as JPG files
- Number consecutively
- Provide a descriptive heading/legend
- Place abbreviations immediately below the table
- Use superscript a, b, c… as identifiers
- Supply Line Art 900 dpi, Combination (Line Art + Halftone) 900 dpi, Halftone 300 dpi
- Graphics downloaded from Web pages are NOT acceptable
- Submit multi-panel figures, ie with parts labeled a,b,c,d, as one file
Supplementary Data
Any supplementary data should be kept to 6 typeset pages or 2,400 words. If you have any more than this you should provide a link to the supplementary data on an external website, your institute’s website for example, and/or Dove Medical Press may be able to upload the raw supplementary data to the http://www.dovepress.com/ website and provide a link in your paper. We welcome video files either as supplementary data or as part of the actual manuscript to show operations, procedures, etc.
Letter to the Editor
Manuscripts submitted as a Letter to the Editor:
- Should relate to a paper previously published in a Dove Medical Press journal, or address an issue of wider concern within the scope of the journal;
- Have a word count of no more than 3,600 words;
- May contain figures and tables (see specifications for these above);
- Have references formatted in the Dove Medical Press style.
Submission of Manuscript
- All manuscripts should be submitted via our website.
- By doing so you agree to the terms and conditions of submission
- Keep a backup and hard copies of the material submitted
Pre-submissions
- Authors are welcome to send an abstract or draft manuscript to obtain a view from the Editor about the suitability of their paper. Please email here and include which journal you are interested in submitting your manuscript to. Our Editors will do a quick review (not peer review) of your paper and advise if they believe it is appropriate for submission to their journal. This will be based on subject matter vs the aims and scope of the journal. It will not be a full review of your manuscript.
Reference Style
See Reference Style Guidelines
Proofs
- You will receive the typeset page proofs for approval
- Check amendments made by the editor have not rendered the material inaccurate
- Check you have answered all the editor’s queries
- Ensure your corrections are minimal and absolutely necessary
- Mark the adjustments clearly in the text and margins, and keep a copy of what you send to the editor
- Notify the editorial office of all corrections within 72 hours of your receipt of the material
- Ensure all authors sign and return the Author Approval and final page of Publication Agreement
All Dove journals are members of and subscribe to the principles of the Committee on Publication Ethics (COPE).
We also support the international standards for editors and authors that were developed at the 2nd World Conference on Research Integrity in Singapore in 2010.
Editorial Board
Dr Walker
Founding Editor: Dr Richard F Walker
Dr Richard F Walker has broad experience in the theoretical and practical aspects of aging research derived from key positions in academia, industry. His education includes a BS in pharmacy (Rutgers University), an MS in biochemistry (New Mexico State University) and a PhD in endocrine physiology (Rutgers University). Postdoctoral training in Neuroendocrinology and Neuropharmacology of Aging was received at the Center for the Study of Aging and Human Development, Duke University Medical Center and at the University of California, Berkeley. Dr Walker has held academic positions in Clemson University, Sanders-Brown Research Center on Aging at the University of Kentucky Medical Center, Medical College of Pennsylvania and the University of South Florida College of Medicine. Consistent with a productive record of research as evidenced by extensive peer-reviewed publications, many federal, state, local grants including those from the NIH (NIA), NSF and DoD, as well as accomplishments in teaching and service, he was twice awarded tenure. Dr Walker also held administrative positions at his last institution that included Director of Research Compliance and Director of the Clinical Alliance for Research, Education and Service. While in the pharmaceutical industry, he held a director level position in research and development at SmithKline Beecham, Inc and he currently consults for a number of companies through his own corporation. Dr Walker successfully prepared several investigational new drug applications (IND’s) to the FDA for studying hormone replacement in aging subjects, and with his colleague Dr Barry Bercu, has organized and co-chaired many international symposia on clinical interventions in aging. Consistent with his goal to promote evidence-based approaches to healthy aging, Dr Walker is coordinating development of the Society for Applied Research in Aging (SARA), which is devoted to that purpose. SARA’s official journal will be Clinical Interventions in Aging. Under his direction as founding editor it will provide a ethical forum for presentation of data and debate on issues relevant to medical practice that is less concerned with treating intrinsic diseases of aging than with sustaining health and vitality throughout life.
Dr Angehrn
Associate Editor in Chief
Associate editor (Europe): Fiorenzo Angehrn
Fiorenzo Angehrn received his medical degree from the University of Zurich, Switzerland. Subsequently, he received postgraduate training in General Surgery in hospitals at Zurich, Glarus, and Biel-Bienne. His subspecialty training was taken at several outstanding Departments of Vascular Surgery including those at the University of Ulm, Germany, University of Bern, Switzerland, and Baylor University in Dallas, Texas, USA. His scientific interests focus on the clinical values of diagnostic methods including blood tests, scintigraphy, and sonography. Throughout his career, Dr Angehrn has been interested in developing interventions to maintain health and vitality across the life span. Evidence of this interest can be found in some of his works such as his book entitled Venenleiden Sind Vermeidbar (Venous Disorders Can be Avoided). To promote this interest among his colleagues he founded and currently presides over the Schweizerische Gesellschaft fur Medizinisches Anti-Aging (Swiss Society for Anti-Aging Medicine). In recognition of his work, Dr Angehrn has been an invited speaker at many prestigious anti-aging meetings and has received significant support from public and private sources for his efforts to promote the ethical and professional advancement of longevity medicine.
Dr Tsubota
Associate Editor in Chief
Associate editor (Asia) Kazuo Tsubota
Internationally recognized dry eye specialist Professor Kazuo Tsubota has been working on the pathogenesis and treatment of dry eye. Professor Tsubota is Chairman of the Department of Ophthalmology at Keio University School of Medicine, his alma mater. He heads a very large and active dry eye research group as well as the largest refractive group in Japan. Dr. Tsubota has many research projects underway in the field of ophthalmology as well as anti-aging medicine in relation to ophthalmology. His basic research in the field of anti-aging medicine in ophthalmology focuses on the mechanism of age-related macular degeneration, which is one of the leading causes of blindness in western countries, and the second most common cause in Japan. Prof. Tsubota is the Editor-in-Chief of Anti-Aging Medicine, the journal of the Japanese Anti-Aging Society. http://www.tsubota.ne.jp
Professor Wu
Associate Editor in Chief
Associate Editor - China: Zhi-Ying Wu
Dr. Zhi-Ying Wu graduated from Fujian Medical University in 1990 and was trained as an attending neurologist and specialist for neurogenetic disorders from 1990 to 1996 at First Affiliated Hospital of Fujian Medical University. During this time, she received her research training in human genetics and molecular biology at the State Key Laboratory of Genetic Engineering of Fudan University and began to focus on molecular diagnoses, mechanisms of and therapies for Wilson’s disease (WD) and facioscapulohumeral muscular dystrophy (FSHD). In 1999, she received her Ph.D. degree in Neurology from Tongji Medical University. From February 2001 to December 2003, she obtained her postdoctoral training in cell biology and mouse genetics at Columbia University and focused on the mechanisms of and therapies for multiple sclerosis (MS). She was introduced as a distinguished professor of Huashan Hospital, Fudan University in 2007 and focused her research work on paroxysmal kinesigenic dyskinesia (PKD), Alzheimer’s disease (AD), spinocerebellar ataxia (SCA) and Huntington’s disease (HD), besides WD and MS. For her achievements in research, she was selected one of the candidates for “Ten Million Talent Project of the New Century” in 2006, the 10th China Youth Science and Technology Award in 2007, Winner of National Outstanding Youth Science Foundation in 2011 and the 9th China Young Women Scientists’ Award in 2012. Currently, Dr. Wu is a Chief physician, professor and tutor of Ph.D. students in Department of Neurology, Huashan Hospital and the director of Institute of Neurology, Fudan University.
|
刊名字顺( Alphabetical List of Journals):
返回页首 